Yu Cui1, Hequn Chen1, Lin Qi1, Xiongbing Zu1, Yang Li2. 1. Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan 410000, China. 2. Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan 410000, China. Electronic address: liyangurology@126.com.
Abstract
PURPOSE: The aim of the study was to evaluate the efficacy of alvimopan on accelerates gastrointestinal recovery after radical cystectomy. METHODS: We searched for all studies investigating alvimopan for bladder cancer patients undergoing radical cystectomy in Pubmed, Web of Knowledge, and the Cochrane Central Search Library. A systematic review and meta-analysis were performed. All studies that compared alvimopan with control group for patients undergoing radical cystectomy were included. Studies with overlapping or insufficient data were excluded. No language restrictions were made. Efficacy was assessed by the time to first toleration of clear liquids, first toleration of solid food, first bowel movement and length of stay. RESULTS: Our searches identified 5 studies, including 613 patients. A total of 294 (47%) patients took alvimopan. On meta-analysis, alvimopan reduced time to first toleration of clear liquids (HR 1.34, 95% CI 1.19 to 1.51, p < 0.001), first toleration of solid food (HR 1.22, 95% CI 1.11 to 1.34, p < 0.001), first bowel movement (HR 1.27, 95% CI 1.12 to 1.43, p < 0.001) and length of stay (HR 1.17, 95% CI 1.10 to 1.25, p < 0.001). CONCLUSIONS: This meta-analysis has shown that alvimopan significantly accelerates recovery of gastrointestinal function and reduces the length of stay in patients performed radical cystectomy. More large scale, multicenter randomized controlled studies are needed before final clinical recommendations can be made.
PURPOSE: The aim of the study was to evaluate the efficacy of alvimopan on accelerates gastrointestinal recovery after radical cystectomy. METHODS: We searched for all studies investigating alvimopan for bladder cancerpatients undergoing radical cystectomy in Pubmed, Web of Knowledge, and the Cochrane Central Search Library. A systematic review and meta-analysis were performed. All studies that compared alvimopan with control group for patients undergoing radical cystectomy were included. Studies with overlapping or insufficient data were excluded. No language restrictions were made. Efficacy was assessed by the time to first toleration of clear liquids, first toleration of solid food, first bowel movement and length of stay. RESULTS: Our searches identified 5 studies, including 613 patients. A total of 294 (47%) patients took alvimopan. On meta-analysis, alvimopan reduced time to first toleration of clear liquids (HR 1.34, 95% CI 1.19 to 1.51, p < 0.001), first toleration of solid food (HR 1.22, 95% CI 1.11 to 1.34, p < 0.001), first bowel movement (HR 1.27, 95% CI 1.12 to 1.43, p < 0.001) and length of stay (HR 1.17, 95% CI 1.10 to 1.25, p < 0.001). CONCLUSIONS: This meta-analysis has shown that alvimopan significantly accelerates recovery of gastrointestinal function and reduces the length of stay in patients performed radical cystectomy. More large scale, multicenter randomized controlled studies are needed before final clinical recommendations can be made.
Authors: Sebastian Karl Frees; Jonathan Aning; Peter Black; Werner Struss; Robert Bell; Claudia Chavez-Munoz; Martin Gleave; Alan I So Journal: World J Urol Date: 2017-11-07 Impact factor: 4.226